BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 389 filers reported holding BIO-TECHNE CORP in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $236,000 | -69.0% | 544 | -63.0% | 0.00% | -66.7% |
| Q4 2021 | $761,000 | +8.9% | 1,471 | +1.9% | 0.01% | 0.0% |
| Q3 2021 | $699,000 | -30.4% | 1,443 | -35.3% | 0.01% | -33.3% |
| Q2 2021 | $1,004,000 | +47.4% | 2,229 | +25.1% | 0.01% | +28.6% |
| Q1 2021 | $681,000 | +21.8% | 1,782 | +1.2% | 0.01% | +16.7% |
| Q4 2020 | $559,000 | +28.2% | 1,760 | 0.0% | 0.01% | +20.0% |
| Q3 2020 | $436,000 | -2.2% | 1,760 | +4.1% | 0.01% | -16.7% |
| Q2 2020 | $446,000 | -99.9% | 1,690 | -21.3% | 0.01% | -14.3% |
| Q1 2020 | $407,114,000 | -3.1% | 2,147 | +12.2% | 0.01% | +16.7% |
| Q4 2019 | $420,142,000 | -47.0% | 1,914 | -52.8% | 0.01% | -40.0% |
| Q3 2019 | $793,050,000 | -18.2% | 4,053 | -12.9% | 0.01% | -23.1% |
| Q2 2019 | $969,687,000 | -2.4% | 4,651 | -7.1% | 0.01% | -7.1% |
| Q1 2019 | $993,544,000 | +47.9% | 5,004 | +7.8% | 0.01% | +27.3% |
| Q4 2018 | $671,645,000 | -16.1% | 4,641 | +18.3% | 0.01% | 0.0% |
| Q3 2018 | $800,927,000 | +32.1% | 3,924 | -4.2% | 0.01% | +37.5% |
| Q2 2018 | $606,299,000 | +69.9% | 4,098 | +73.4% | 0.01% | +60.0% |
| Q1 2018 | $356,908,000 | – | 2,363 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |